Articles from Edison Oncology Holding Corp.

Edison Oncology Appoints Michael Faber to Board of Directors and Announces Five Poster Presentations at Two Peer-Reviewed Oncology Meetings in November 2026

Presentations at 2026 Society for NeuroOncology Annual Meeting and the EORTC-NCI-AACR Symposium highlight the Company's EO3001, EO4426 and EO1001 programs

By Edison Oncology Holding Corp. · Via ACCESS Newswire · October 20, 2026

Edison Oncology and Senz Oncology Complete Enrollment in Phase 1-2a Trial of EO1001, Advancing Development in ErbB-Driven Cancers

Early clinical activity observed across multiple ErbB-driven tumor types, including EGFR extracellular domain (ECD)-mutant cancers, for which no approved targeted therapies currently exist

By Edison Oncology Holding Corp. · Via ACCESS Newswire · July 30, 2026